Where is QURE stock listed?

uniQure N.V. trades under the ticker QURE on NASDAQ.

How can I research QURE's financials and filings?

Vantafin provides uniQure N.V.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the QURE profile.

uniQure N.V. (QURE) stock profile

uniQure N.V. is a gene therapy company focused on developing treatments for patients with genetic and other devastating diseases. Its lead program is etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for hemophilia B. The company is also developing AMT-130, a gene therapy in Phase I/II clinical study for Huntington's disease; AMT-060, in Phase I/II clinical trial for hemophilia B; AMT-210 for Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical candidate for autosomal dominant Alzheimer's disease; and AMT-161 for amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Key facts

Symbol	QURE
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology
CEO	Matthew Craig Kapusta
Employees	209
Headquarters	Amsterdam, NL
IPO	2014-02-05
Website	www.uniqure.com

Explore QURE on Vantafin

Frequently asked questions

What does uniQure N.V. (QURE) do?: uniQure N.V. is a gene therapy company focused on developing treatments for patients with genetic and other devastating diseases. Its lead program is etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for hemophilia B. The company is also developing AMT-130, a gene therapy in Phase I/II clinical study for Huntington's disease; AMT-060, in Phase I/II clinical trial for hemophilia B; AMT-210 for Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical candidate for autosomal dominant Alzheimer's disease; and AMT-161 for amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Where is QURE stock listed?: uniQure N.V. trades under the ticker QURE on NASDAQ.
How can I research QURE's financials and filings?: Vantafin provides uniQure N.V.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the QURE profile.

uniQure N.V. (QURE) stock profile

Key facts

Symbol	QURE
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology
CEO	Matthew Craig Kapusta
Employees	209
Headquarters	Amsterdam, NL
IPO	2014-02-05
Website	www.uniqure.com

Explore QURE on Vantafin

Frequently asked questions

What does uniQure N.V. (QURE) do?: uniQure N.V. is a gene therapy company focused on developing treatments for patients with genetic and other devastating diseases. Its lead program is etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for hemophilia B. The company is also developing AMT-130, a gene therapy in Phase I/II clinical study for Huntington's disease; AMT-060, in Phase I/II clinical trial for hemophilia B; AMT-210 for Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical candidate for autosomal dominant Alzheimer's disease; and AMT-161 for amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Where is QURE stock listed?: uniQure N.V. trades under the ticker QURE on NASDAQ.
How can I research QURE's financials and filings?: Vantafin provides uniQure N.V.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the QURE profile.